2020
DOI: 10.1016/j.jcjd.2020.02.003
|View full text |Cite
|
Sign up to set email alerts
|

Severity Grade Assessment Classifications for Both Insulin Resistance Syndrome and Status of Pancreatic Beta Cell Function in Clinical Practice Using Homeostasis Model Assessment Method Indices

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 27 publications
0
3
0
Order By: Relevance
“…C-peptide is more stable and is considered an effective substitute for insulin. 29 Moreover, the bone density we measured was based on the lumbar spine, which might also cause inconsistent results. It has been reported 30 that significant insulin resistance in T2DM patients is associated with low bone density.…”
Section: Discussionmentioning
confidence: 99%
“…C-peptide is more stable and is considered an effective substitute for insulin. 29 Moreover, the bone density we measured was based on the lumbar spine, which might also cause inconsistent results. It has been reported 30 that significant insulin resistance in T2DM patients is associated with low bone density.…”
Section: Discussionmentioning
confidence: 99%
“…With regard to the evaluation method of IR, the gold standard is the euglycemic-hyperinsulinemic clamp, and others include the insulin suppression test, 2 homeostasis model assessment-IR, 3 and the quantitative insulin sensitivity check index. 4 Because of the difficulty in technical use of these methods, their overall complexity, and the nature of the population, their clinical applications are relatively limited.…”
Section: Introductionmentioning
confidence: 99%
“…Evaluation of islet function is important for patients with T2DM because it is usually used to assess the progress of T2DM and to guide drug usage. Traditionally, homeostasis model assessment (HOMA)-β has been used to evaluate islet function using fasting blood glucose (FBG) and insulin levels [1], but this is only used in patients who have not received insulin therapy; therefore, its application is limited for patients who have received injected insulin. Li [2] found that a modified HOMA-β that replaces insulin with fasting C-peptide (FCP) could be used in all patients whether or not they have taken insulin.…”
Section: Introductionmentioning
confidence: 99%